PHARMACEUTICAL giant GSK’s multi-million pound investment in Worthing will secure the town’s ageing facility for the ‘foreseeable future’.
The Southdownview Way factory, which has produced antibiotic Augmentin for over 30 years, has unveiled plans for a £100million investment project.
Coupled with a recent £20million investment, the firm has submitted a planning application for a new production facility, which will increase capacity by 75 per cent.
The ongoing investment will secure the long-term future of the plant, which was at one stage facing closure.
Site director Kirk Brown said: “We are really excited. This investment, if you will, confirms and continues to mean activity for one of the key brands in the area carries on for the foreseeable future.
“We looked at moving operations to various different locations and ultimately Worthing came out on top.”
The combination of the site’s legacy, skilled workforce and Patent Box legislation, which provides an incentive for UK investment, persuaded the firm to remain in Worthing.
As a result, it claims 200 production jobs will be secured, while the construction will create 150 temporary positions.
For the full story, see the Worthing Herald, out Thursday, February 6.